Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha

Liver

Volumn 22, Issue 4, 2002, Pages 317-320

  Forrest, Ewan H ^a,c   Oien, K A ^a   Dickson, S ^a   Galloway, D ^a,b   Mills, P R ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Cholestasis; Parenteral nutrition (MeSH: parenteral nutrition, total); Tumour necrosis factor alpha (MeSH: tumour necrosis factor)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CODEINE PHOSPHATE; FAT; GLUCOSE; INFLIXIMAB; INTRALIPID; NITROGEN; OMEPRAZOLE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; BIOCHEMISTRY; CASE REPORT; CHOLESTASIS; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; ENTEROCUTANEOUS FISTULA; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER DYSFUNCTION; SMALL INTESTINE DISEASE; SMALL INTESTINE RESECTION; TOTAL PARENTERAL NUTRITION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CHOLESTASIS; CROHN DISEASE; FEMALE; HUMANS; MIDDLE AGED; PARENTERAL NUTRITION, TOTAL; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036696890     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2002.01649.x     Document Type: Article

References (12)

1. QUIGLEY E M M, MARSH M N, SHAFFER J L, et al. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993; 104: 286-301.
2. BELL S, KAMM M. Antibodies to tumour necrosis factor α as treatment for Crohn's disease. Lancet 2000; 355: 858-860.
3. WEWER V, GLUUD C, SCHLICHTING P, et al. Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1991; 26: 97-102.
4. REIGLER G, D'INCA R, STURNIOLO G C, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Scand J Gastroenterol 1998; 33: 93-8.
5. STANKO R T, NATHAN G, MENDELOW H, et al. Development of hepatic cholestasis and fibrosis in patients with massive loss of intestine supported by prolonged parenteral nutrition. Gastroenterology 1987; 92: 197-202.
6. BENGOA J M, HANAUER S B, SITRIN M D, et al. Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology 1985; 5: 79-84.
7. CAVICCHI M, BEAU P, CRENN P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Int Med 2000; 132: 525-32.
8. MERRITT R J, SINATRA F R, HENTON D H, et al. Cholestatic effect of intraperitoneal administration of tryptophan to suckling rat pups. Pediatr Res 1984; 18: 904-7.
9. BELLI D C, Roy C C, FOURNIER L-A, TUCHWEBER B, GIGUERE R, YOUSEF I M. The effect of taurine on the cholestatic potential of sulfated lithocholate and its conjugates. Liver 1991; 11: 162-9.
10. YOSHIOKA K, KAKUMU S, ARAO M, et al. Immunohistochemical studies of intrahepatic tumour necrosis factor in chronic liver diseases. J Clin Pathol 1990; 43: 298-302.
11. WHITING J F, GREEN R M, ROSENBLUTH A B, et al. Tumour necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology 1995; 22: 1273-8.
12. PAPPO I, BERCOVIER H, BERRY E, et al. Anti-tumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. J Parenter Enteral Nutr 1995; 19: 80-2.